(Xiamen, China — November 22, 2019) Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE:300685), a leading company in companion diagnostics for precision oncology, today announced that recently it signed a diagnostic partnership agreement with Eisai Co., Ltd., one of leading pharmaceutical companies in Japan, for the development and registration of companion diagnostic tests.
“At AmoyDx, we have been developing highly effective diagnostic solutions to guide treatment decision of clinical precision oncology based on various technical platforms. Patients’ benefit is always the first consideration for our product development”, said Dr. Li-mou Zheng, founder and CEO of AmoyDx. “We are happy to have the opportunity of working together with Eisai on the emerging valuable targets. We are expecting the success of Eisai’s excellent targeted medicines to bring benefit to the patients in Japan, China and other countries.”
About AmoyDx
Amoy Diagnostics Co., Ltd. (AmoyDx) is the pioneer and globally leading company in the field of molecular diagnostics for precision oncology, focusing at companion diagnostics product development and commercialization. A rich product portfolio has been established with more than twenty of products approved by China NMPA, EU authority, Japan PMDA, South Korea KFDA, etc. Patients in more than 50 countries and regions are benefiting from AmoyDx products. With multiple technological platforms and full capability of companion diagnostics product development and commercialization, AmoyDx has become important diagnostic partner of many pharmaceutical companies over the globe. For more information, please visit our website: www.amoydx.com.
About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries. For more information about Eisai Co., Ltd., please visit www.eisai.com/.